The pharmacokinetics of piperacillin were studied in a total of 26 Caucasian normal male
volunteers. Single intramuscular doses of 0.5, 1.0, and 2.0 g were given to three groups …

Our results suggest a 4 times increased risk of neutropenia associated with piperacillin-
tazobactam compared with ticarcillin-clavulanic acid. Piperacillin-tazobactam should be …

Many antimicrobial medications may be administered to paediatric patients with a degree of
impunity because they are relatively non-toxic and have a wide therapeutic margin …

A 1: 4 by weight of combination of tazobactam, a new β-lactamase inhibitor, and piperacillin,
is now under development in Japan. After bolus iv administration of the combination to …

Piperacillin/tazobactam is the most recently approved combination of a β-lactam agent with
an inhibitor of bacterial β-lactamases. It has a broader spectrum than do preceding inhibitor …

The first year of life is associated with major changes in the processes affecting the
absorption, distribution, metabolism and excretion of drugs. Drug absorption by the oral …

An in vitro pharmacokinetic model was used to study the pharmacodynamics of piperacillin-
tazobactam and piperacillin-sulbactam against gram-negative bacilli producing plasmid …

Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

The pharmacokinetics of tazobactam and piperacillin in plasma and different tissues after a
30-min intravenous infusion of 4 g of piperacillin and 0.5 g of tazobactam were investigated …

The pharmacodynamics in neonates are different from those in adults and children because
the absorption, distribution, metabolism and excretion of drugs in neonates are always …